Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
5 Nov 21
Current reports
8-K
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
8-K
Termination of a Material Definitive Agreement
16 Feb 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Nov 23
8-K
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Termination of a Material Definitive Agreement
8 Sep 23
8-K
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Regulation FD Disclosure
7 Aug 23
8-K
Departure of Directors or Certain Officers
22 Jun 23
Registration and prospectus
D
$30.00 mm in equity / options, sold $30.00 mm, 1 investor
19 Mar 24
S-8
Registration of securities for employees
11 Aug 23
S-8
Registration of securities for employees
5 Aug 22
S-8
Registration of securities for employees
18 Aug 21
S-3ASR
Automatic shelf registration
12 Mar 21
S-8
Registration of securities for employees
7 Aug 20
S-8
Registration of securities for employees
29 Jun 18
D
$850M in equity, sold $850M, 1 investor
3 Apr 18
S-8
Registration of securities for employees
15 Jun 17
424B5
Prospectus supplement for primary offering
19 Oct 16
Proxies
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
Other
UPLOAD
Letter from SEC
13 Dec 21
CORRESP
Correspondence with SEC
9 Nov 21
UPLOAD
Letter from SEC
26 Oct 21
UPLOAD
Letter from SEC
8 Feb 19
CORRESP
Correspondence with SEC
7 Dec 18
UPLOAD
Letter from SEC
19 Nov 18
CT ORDER
Confidential treatment order
22 May 18
UPLOAD
Letter from SEC
16 Jan 18
CORRESP
Correspondence with SEC
27 Dec 17
CT ORDER
Confidential treatment order
19 Dec 17
Ownership
SC 13G
TCG Crossover GP II, LLC
15 Mar 24
3
DAVID KROIN
14 Mar 24
4
Jonathan Zalevsky
22 Feb 24
4
Mark Andrew Wilson
22 Feb 24
4
HOWARD W ROBIN
22 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24